Loading clinical trials...
Loading clinical trials...
A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer
Conditions
Interventions
bleomycin sulfate
filgrastim
+5 more
Locations
37
Austria
Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital
Vienna (Wien), Austria
Institut Jules Bordet
Brussels (Bruxelles), Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
Aarhus University Hospital - Aarhus Sygehus - Norrebrogade
Aarhus, Denmark
Rigshospitalet - Copenhagen University Hospital
Copenhagen, Denmark
Start Date
April 1, 1999
Primary Completion Date
June 1, 2007
Last Updated
September 24, 2012
NCT05735080
NCT04657068
NCT07197671
NCT04585750
NCT05831579
NCT04900818
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions